Lamivudine Aurobindo

Lamivudine, the active ingredient in Lamivudine Aurobindo, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for systemic use. It is employed in the management of human immunodeficiency virus (HIV) infection and chronic hepatitis B infection in adult patients, and is marketed in the European Union.

GNH USA supplies Lamivudine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks across Europe, Asia and the Americas. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Lamivudine is used as an antiretroviral and antiviral agent targeting viral replication pathways.

- HIV infection: reduces viral load and improves immune function in adults. - Chronic hepatitis B infection: suppresses HBV DNA replication and helps achieve serologic response. - HIV‑1 infection in combination therapy: forms part of standard HAART regimens to enhance treatment efficacy.

Lamivudine may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Fatigue: general tiredness reported by some patients. - Diarrhea: loose stools, usually transient.

Serious or Rare Side Effects: - Lactic acidosis: rare metabolic complication requiring immediate medical attention. - Severe hepatotoxicity: marked liver enzyme elevation or liver failure. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

When prescribing Lamivudine, clinicians should consider several precautionary measures to ensure safe use. - Renal function: assess creatinine clearance and adjust dose in severe impairment. - Hepatic disease: monitor liver enzymes regularly in patients with existing liver conditions. - Pregnancy: evaluate risk‑benefit ratio, as safety data are limited. - Concomitant medications: review for potential drug‑drug interactions before initiating therapy. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Lamivudine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Didanosine: co‑administration increases risk of pancreatitis and hepatic toxicity. - Stavudine: combined use may exacerbate mitochondrial toxicity and lactic acidosis.

Moderate Interactions (Monitor Closely): - Tenofovir: may require renal function monitoring due to additive nephrotoxic potential. - Efavirenz: can affect Lamivudine plasma levels; monitor viral load. - Rifampicin: induces hepatic enzymes, potentially reducing Lamivudine concentrations.